Moleculin Biotech has announced a public stock offering priced at 75 cents per share to raise $9.3 million for its clinical programs, resulting in a significant drop of 63.53% in its stock price, raising concerns among investors about potential dilution. In related news, preliminary results from the MIRACLE trial indicated a 24% complete remission rate among participants, with recruitment nearing completion at 74 out of 90 planned subjects across 33 sites. The trial, focused on second-line leukemia patients, is ongoing, with full unblinding expected between December 2026 and February 2027, and no signs of cardiotoxicity reported thus far.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.benzinga.com/news/health-care/26/07/60850306/moleculin-biotech-stock-is-sinking-friday-whats-going-on
